Showing 4001-4010 of 5646 results for "".
- GenSight Reports Topline Efficacy and Safety Results at 3 Years Post-Treatment with Lumevoqhttps://modernod.com/news/gensight-reports-topline-efficacy-and-safety-results-at-3-years-post-treatment-with-lumevoq/2481464/GenSight Biologics reported topline efficacy and safety results at 3 years post-treatment administration in the REFLECT phase 3 clinical trial with Lumevoq (lenadogene nolparvovec). The results show sustained efficacy and favorable safety for bilateral intravitreal injection of the gene
- Grants Available for Students, Residents to Attend Neuro-Optometric Rehabilitation Association 2023 Conferencehttps://modernod.com/news/grants-available-for-students-residents-to-attend-neuro-optometric-rehabilitation-association-2023-conference-2023-conferenc/2481463/The Neuro-Optometric Rehabilitation Association International (NORA) is offering up to 10 students and residents with an interest in neuro-rehabilitation an opportunity to apply for a student grant (
- Visionix Unveils Second Generation VX 650 Multimodal Screener at Vision Expo 2023https://modernod.com/news/visionix-unveils-second-generation-vx-650-multimodal-screener-at-vision-expo-2023/2481461/Visionix announces a new multimodal device update with its second-generation VX 650. Launched in 2021, the VX 650 is an advanced anterior segment analyzer with retinal imaging. The enhanced wavefront-based aberrometer's "quick mode" and new capture flexibilities can decrease screeni
- Sight Sciences Launches the Ergo-Series of the OMNI Surgical Systemhttps://modernod.com/news/sight-sciences-launches-the-ergo-series-of-the-omni-surgical-system/2481457/Sight Sciences announced the US launch of the Ergo-Series of the OMNI Surgical System, a technology designed to facilitate surgeons’ ability to perform minimally invasive, implant-free glaucoma procedures in adults with primary open-angle glaucoma. The OMNI Sur
- Pioneers in Retinal Gene Therapies Awarded International Harrington Prizehttps://modernod.com/news/pioneers-in-retinal-gene-therapies-awarded-international-harrington-prize/2481453/The tenth annual Harrington Prize for Innovation in Medicine has been jointly awarded to Jean Bennett, MD, PhD, the F.M. Kirby Emeritus Professor of Ophthalmology and Cell and Developmental Biology at the Perelman School of Medicine at the University of Pennsylvania;
- NIH: Eye Experts Weigh In on Artificial Tears in Midst of Infectious Outbreakhttps://modernod.com/news/nih-eye-experts-weigh-in-on-artificial-tears-in-midst-of-infectious-outbreak/2481452/The Centers for Disease Control and Prevention (CDC) is investigating how the virulent strain of P. aeruginosa ended up in EzriCare and Delsam Pharma artificial tears. According to an
- EyeBio Announces First Asset in Pipeline of Retinal Disease Treatments and Appoints New Members to Executive Teamhttps://modernod.com/news/eyebio-announces-first-asset-in-pipeline-of-retinal-disease-treatments-and-appoints-new-members-to-executive-team/2481448/Eyebiotech Limited announced several appointments to its executive team and announced details on Restoret, the first asset in a pipeline of multi-specific agonist antibodies. EyeBio announced the following appointments to the senior leadership team: Anthony P. Adami
- Post-Hoc Analysis Shows Up to a 59% Reduction in Rate of Vision Loss in Iveric Bio's GA Treatmenthttps://modernod.com/news/iveric-bio-announces-up-to-a-59-reduction-in-rate-of-vision-loss-in-geographic-atrophy-treatment-trials/2481439/Iveric bio announced an exploratory time-to-event analysis from the avacincaptad pegol (ACP) GATHER clinical trial program evaluating reduction in vision loss with ACP 2 mg versus sham treatment. The GATHER1 and GATHER2 clinical trials were designed to evaluate the rate of geographic at
- New Data Suggest Uplinza for the Treatment of NMOSD Did Not Increase the Risk of COVID-19 or Reduce Antibody Levels From Childhood Vaccineshttps://modernod.com/news/new-data-suggest-uplinza-for-the-treatment-of-nmosd-did-not-increase-the-risk-of-covid-19-or-reduce-antibody-levels-from-childhood-vaccines/2481438/Horizon Therapeutics announced new data suggest Uplinza does not increase susceptibility to COVID infection or deplete childhood vaccine-generated antibodies. Uplinza is the first and only B-cell-depleting monotherapy approved by the FDA and the European Commission for the tre
- Glaukos Submits NDA to FDA for iDose TRhttps://modernod.com/news/glaukos-submits-nda-to-fda-for-idose-tr/2481434/Glaukos announced the submission of a new drug application (NDA) to the FDA for iDose TR, a micro-invasive intraocular implant designed to continuously deliver therapeutic levels of a proprietary formulation of travoprost from within the eye for extended periods of time.&